Palisade Bio (PALI) Amortization of Deferred Charges (2013 - 2017)
Palisade Bio (PALI) reported Amortization of Deferred Charges of $12127.0 for Q2 2017, down 15.57% year-over-year from $14363.0 in Q2 2016, and down 74.55% on a QoQ basis from $47654.0 in Q1 2017.
Palisade Bio (PALI) has 5 years of Amortization of Deferred Charges data on file, last reported at $12127.0 in Q2 2017.
- Quarterly Amortization of Deferred Charges fell 15.57% year-over-year to $12127.0 in Q2 2017, while the trailing twelve-month figure through Dec 2017 was $59781.0 (down 82.8% YoY) and the FY2017 annual result came in at $59781.0, down 82.8% from the prior year.
- Amortization of Deferred Charges eased to $12127.0 in Q2 2017 per PALI's latest filing, from $47654.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $231381.0 in Q4 2013 and bottomed at $12127.0 in Q2 2017.
- The 5-year median for Amortization of Deferred Charges is $207350.5 (2014), against an average of $155644.9.
- The widest annual swing landed in 2014, when Amortization of Deferred Charges jumped 881.51%; it then tumbled 93.42% in 2016.
- Tracing PALI's Amortization of Deferred Charges over 5 years: stood at $231381.0 in 2013, then fell by 10.37% to $207388.0 in 2014, then grew by 3.88% to $215440.0 in 2015, then plunged by 70.29% to $63998.0 in 2016, then tumbled by 81.05% to $12127.0 in 2017.
- Per Business Quant, the three latest PALI Amortization of Deferred Charges figures stand at $12127.0 (Q2 2017), $47654.0 (Q1 2017), and $63998.0 (Q4 2016).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 12,127.00 |
| Jun 30, 2017 | 12,127.00 |
| Mar 31, 2017 | 47,654.00 |
| Mar 31, 2017 | 47,654.00 |
| Dec 31, 2016 | 63,998.00 |
| Dec 31, 2016 | 63,998.00 |
| Sep 30, 2016 | 79,668.00 |
| Sep 30, 2016 | 79,668.00 |
| Jun 30, 2016 | 14,363.00 |
| Jun 30, 2016 | 14,363.00 |
| Mar 31, 2016 | 189,462.00 |
| Mar 31, 2016 | 189,462.00 |
| Dec 31, 2015 | 215,440.00 |
| Dec 31, 2015 | 215,440.00 |
| Sep 30, 2015 | 221,494.00 |
| Sep 30, 2015 | 221,494.00 |
| Jun 30, 2015 | 218,414.00 |
| Jun 30, 2015 | 218,414.00 |
| Mar 31, 2015 | 215,182.00 |
| Mar 31, 2015 | 215,182.00 |
| Dec 31, 2014 | 207,388.00 |
| Dec 31, 2014 | 207,388.00 |
| Sep 30, 2014 | 190,136.00 |
| Sep 30, 2014 | 190,136.00 |
| Jun 30, 2014 | 207,313.00 |
| Jun 30, 2014 | 207,313.00 |
| Mar 31, 2014 | 224,795.00 |
| Mar 31, 2014 | 224,795.00 |
| Dec 31, 2013 | 231,381.00 |
| Dec 31, 2013 | 231,381.00 |
| Sep 30, 2013 | 223,672.00 |
| Sep 30, 2013 | 223,672.00 |
| Jun 30, 2013 | 216,219.00 |
| Jun 30, 2013 | 216,219.00 |
| Mar 31, 2013 | 22,903.00 |
| Mar 31, 2013 | 22,903.00 |